2024 Market Insights: Insulin Glargine Biosimilars
Insulin glargine, a long-acting insulin analog, is a cornerstone in diabetes management, providing consistent glucose control over 24 hours. With the global prevalence of diabetes on the rise, insulin glargine biosimilars offer an affordable alternative to branded products like Sanofi’s Lantus, helping to alleviate the economic challenges of diab